HPS Pharmacies wish to give notice that Eli Lilly is discontinuing Effient® as follows:
Both strengths of Effient® will be deleted from the Australian market on 31 July 2020.
Prasugrel is a P2Y12 antagonist indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome who are to undergo percutaneous coronary intervention (PCI). Other P2Y12 antagonists available in Australia are clopidogrel and ticagrelor.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Eli Lilly on 1800 454 559 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates